Neoplastic Effect of Indomethacin in N-methyl-N-nitrosourea Induced Mammary Carcinogenesis in Female Rats

Česká verzia

Authors: P. Kubatka ¹; K. Kalická ²; B. Bojková ²; I. Ahlers ²; E. Ahlersová ²; M. Péč ¹
Authors place of work: Ústav lekárskej biológie, Jesseniova lekárska fakulta, Univerzita Komenského, Martin, Slovenská republika ¹; Katedra fyziológie živočíchov, Ústav biologických a ekologických vied, Prírodovedecká fakulta, Univerzita P. J. Šafárika, Košice, Slovenská republika ²
Published in the journal: Klin Onkol 2012; 25(5): 359-363
Category: Original Articles

Summary

Background:
High levels of prostaglandins found in many neoplastic tissues, especially in colon cancer and breast cancer, suggest a role of cyclooxygenase in the process of carcinogenesis.

Material and methods:
The aim of this study was to analyse the chemopreventive potential of non-steroidal inflammatory drug indomethacin and its combination with pineal hormone melatonin in rat mammary carcinogenesis induced by N-methyl-N-nitrosourea. Indomethacin was administered 3 times a week and melatonin 4 times a week, both substances in a concentration of 20 µg/ml of drinking water. Chemoprevention began approximately 2 weeks before carcinogen administration and lasted until the end of the experiment 25 weeks later.

Results:
Indomethacin administered alone and in combination with melatonin stimulated the growth of mammary tumors. We found a significant increase in the average tumor volume caused by indomethacin alone by 126%, and in combination with melatonin by 104% compared to the control group. Indomethacin administered alone increased the incidence of tumors by 21.5% (also in combination with melatonin) and reduced the tumor latency by 17 days compared to controls. Melatonin alone significantly reduced tumor volume in comparison with control animals. During the long-term administration, both substances were well tolerated by animals.

Conclusion:
Indomethacin, a predominant cyclooxygenase inhibitor-1, showed significant neoplastic effects in the prevention of N-methyl-N-nitrosourea induced rat mammary carcinogenesis. This finding is in strong contrast to our previous experiment, where indomethacin in 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis revealed marked antineoplastic effects.

Key words:
rats – mammary carcinogenesis – chemoprevention – indomethacin – melatonin

Submitted:
23. 2. 2012

Accepted:
30. 4. 2012

Zdroje

1. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10(5): 501–507.

2. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30(1): 3–21.

3. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325(23): 1593–1596.

4. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999; 6(1): 71–73.

5. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000; 7(1): 169–170.

6. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9(4): 693–695.

7. Cotterchio M, Kreiger N, Sloan M et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10(11): 1213–1217.

8. Jang TJ, Jung HG, Jung KH, O MK. Chemopreventive effect of celecoxib and expression of cyclooxygenase-1and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol 2002; 83(4): 173–182.

9. Suzui N, Sugie S, Rahman KM et al. Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyzridine-induced mammary carcinogenesis in rats. Jpn J Cancer Res 1997; 88(8): 705–711.

10. Mocikova-Kalicka K, Bojkova B, Adamekova E et al. Preventive effect of indomethacin and melatonin on 7, 12-dimethybenz/a/anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats. A preliminary report. Folia Biol (Praha) 2001; 47(2): 75–79.

11. Kubatka P, Kalicka K, Chamilova M et al. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma 2002; 49(4): 255–259.

12. Kubatka P, Ahlers I, Ahlersová E et al. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett 2003; 202(2): 131–136.

13. Orendas P, Ahlers I, Kubatka P et al. Etoricoxib in the prevention of rat mammary carcinogenesis. Acta Vet (Brno) 2007; 76(4): 613–618.

14. Orendas P, Kassayova M, Kajo K et al. Celecoxib and melatonin in prevention of female rat mammary carcinogenesis. Neoplasma 2009; 56(3): 250–256.

15. Harris RE, Alshafie GA, Abou-Issa H et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60(8): 2101–2103.

16. Kawamori T, Rao CV, Seibert K et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58(3): 409–412.

17. Grubbs CJ, Lubet RA, Koki AT et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60(20): 5599–5602.

18. Cos S, González A, Martínez-Campa C et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 2008; 8(8): 691–702.

19. Hamid R, Singh J, Reddy BS et al. Inhibition by dietary menhaden oil of cyclooxygenase-1 and 2 in N-nitrosomethylurea-induced rat mammary tumors. Int J Oncol 1999; 14(3): 523–528.

20. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985; 45(4): 1803–1808.

21. Noguchi M, Taniya T, Koyasaki N et al. Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptors contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res 1991; 51(10): 2683–2689.

22. Noguchi M, Ohta N. Influences of high dietary fat and/or indomethacin on tumor proliferation and cell kinetics of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in rats. In Vivo 1993; 7(1): 53–58.

23. Noguchi M, Erashi M, Miyazaki I et al. Effects of indomethacin with or without linoleic acid on human breast cancer cells in vitro. Prostaglandins Leukotr Essent Fatty Acids 1995; 52(6): 381–386.

24. McCormick DL, Moon RC. Indomethacin inhibits mammary carcinogenesis in rats. Proc Int Assoc Breast Cancer Res 1983; 1: 43.

25. Kohl S, Jansen DM, Loo LS. Indomethacin enhancement of human natural killer cytotoxicity to herpes simplex virus infected cells in vitro and in vivo. Prostaglandins Leukot Med 1982; 9(2): 159–166.

26. Shimamura T, Hashimoto K, Sasaki S. Feedback suppression of the immune response in vivo. I. Immune B cells induce antigen-specific suppressor T cells. Cell Immunol 1982; 68(1): 104–113.

27. Gołab J, Kozar K, Kamiński R et al. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci 2000; 66(13): 1223–1230.

28. Nakatsugi S, Ohta T, Kawamori T et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000; 91(9): 886–892.

29. Howard PA, Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004; 43(4): 519–525.

30. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302–1308.

31. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 2005; 13(4): 559–583.

32. Harris RE. Cyclooxygenase-2 /COX-2/ and the inflammogenesis of cancer. In: Harris RE (ed). Inflammation in the Pathogenesis of Chronic Diseases. New York: Springer 2007: 93–126.

33. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Clin Pract 2008; 62(3): 444–449.

34. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of non-steroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100(2): 1439–1447.

35. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27.